Why We Invested in Journey Clinical

We are thrilled to announce that we are investing (again) in Journey Clinical! 🚀

Journey Clinical is a psychedelic medicine infrastructure company that provides therapists with a plug-and-play platform to provide psychedelic-assisted psychotherapy with an initial focus on ketamine.

Myriam Barthes, Jonathan Sabbagh, and the Journey team have achieved remarkable success in transforming their idea to a full-fledged company in a short period of time. We were immediately impressed with Jonathan and Myriam when we first met them over two years ago –  they have a deep understanding of the market as experienced, passionate leaders and they are in the space for the right reasons. 

By bringing psychedelic-assisted therapy to existing therapist-patient relationships, Journey Clinical is making therapy more accessible and effective for those who need it. Journey streamlines the patient workflow by moving aspects online and allows independent practitioners to connect directly with clients, ultimately lowering overall costs for patients.

Journey supports independent therapists by offering in-house prescribing doctors, psychedelic therapy education, a community of peers, and continuous marketing, legal and education resources. Their telehealth platform verifies patient eligibility, tracks outcomes, and monitors for adverse effects. They're expanding the market size by making it easier for practitioners to offer psychedelic-assisted therapy.

The company is starting with ketamine treatments, but plans to expand to other treatments such as psilocybin and MDMA, when approved by regulators. With their platform, Journey Clinical is helping to address the worsening mental health crisis, the shortage of clinicians, and the need for alternative treatments.

We’re joined by a great group of investors including Union Square Ventures, Alley Corp, Fifty Years, Able Partners, Gaingels, Palo Santo Fund, Coalition VC, Mystic Ventures, Colibri Group, Satori Capital, and angel investors. This is USV’s first investment in a psychedelic company and validates our thesis that more traditional investors are seeing the opportunity psychedelic medicine will play in mental healthcare. 

Thanks to Jonathan, Myriam, and the Journey team for the opportunity to invest!

If you want to learn more about Journey Clinical, check out our Business Trip episode: https://www.businesstrip.fm/podcast/episode/7898d244/empowering-the-next-wave-of-psychedelic-therapists-journey-clinical

Onward!

P.S. If you liked reading this, feel free to click the ❤️ button on this post so more people can discover it on Substack 🙏